Trump administration bars public distribution of fentanyl test strips

The Trump administration’s decision to bar public distribution of fentanyl test strips could make it harder for states, tribes and community groups to keep one of the lowest-cost overdose prevention tools in circulation, even as fentanyl and other adulterants continue to show up in the drug supply.

In updated funding guidance issued April 24, the Substance Abuse and Mental Health Services Administration said it is against administration policy to publicly distribute test strips used to detect fentanyl, xylazine and medetomidine. The letter said the move reflected a “clear shift away from harm reduction” and away from practices the administration said facilitate illicit drug use and are incompatible with federal law.

The guidance reverses SAMHSA’s January 31, 2024 position, when the agency said federal funding could be used to buy rapid fentanyl and xylazine test strips in several grant streams. Those included State Opioid Response grants, Tribal Opioid Response grants, the Substance Use Prevention, Treatment, and Recovery Services Block Grant, first responder and overdose prevention programs, and other resources that had helped local agencies put the strips into the hands of people most at risk.

The policy shift lands at a time when overdose deaths have been falling nationally. The Centers for Disease Control and Prevention said in February 2025 that U.S. overdose deaths declined nearly 24% in the 12 months ending September 2024, to about 87,000 from about 114,000 the year before. Even so, public health workers say the decline does not erase the continuing danger posed by fentanyl and the increasingly unpredictable street supply.

That is where the evidence fight sharpens. The National Institute on Drug Abuse says fentanyl test strips are a drug-checking tool and that some people change behavior when a sample tests positive, including using smaller amounts, using more slowly or not using alone. A 2025 study in JAMA Network Open found that fentanyl test strip use was associated with more overdose risk-reduction behaviors.

The new federal stance runs counter to a growing patchwork of state and local policies that had treated the strips as a public health tool rather than drug paraphernalia. As of December 2023, 46 jurisdictions supported access to fentanyl test strips through laws that did not subject possession or use to paraphernalia penalties.

The latest guidance also fits into a broader federal retreat from harm reduction. After Donald Trump’s July 24, 2025 executive order on ending crime and disorder on America’s streets, SAMHSA issued later guidance drawing a bright line against federal support for certain harm reduction supplies, including, in prior language, overdose-reversal medications that had been “lumped into” that category. For local providers, the practical effect is immediate: fewer federal avenues to distribute a cheap tool that can give people a chance to avoid a fatal dose.